The Human Hookworm Vaccine

dc.creatorHotez, Peter Jay
dc.creatorDiemert, David
dc.creatorBacon, Kristina M.
dc.creatorBeaumier, Coreen
dc.creatorBethony, Jeffrey Michael
dc.creatorBottazzi, Maria Elena
dc.creatorBrooker, Simon
dc.creatorCouto, Artur Roberto
dc.creatorFreire, Marcos da Silva
dc.creatorHomma, Akira
dc.creatorLee, Bruce Y.
dc.creatorLoukas, Alex
dc.creatorLoblack, Marva
dc.creatorMorel, Carlos Medicis
dc.creatorOliveira, Rodrigo Corrêa de
dc.creatorRussell, Philip K.
dc.date2018-11-20T11:58:10Z
dc.date2018-11-20T11:58:10Z
dc.date2013
dc.date.accessioned2023-09-26T22:06:05Z
dc.date.available2023-09-26T22:06:05Z
dc.identifierHOTEZ, Peter Jay et al. The Human Hookworm Vaccine. Vaccine. V. 31, Suppl 2, p. B227-32, 2013.
dc.identifier0264-410X
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30107
dc.identifier10.1016/j.vaccine.2012.11.034
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8874744
dc.descriptionO artigo encontra-se em acesso aberto no site do Editor.
dc.descriptionHookworm infection is one of the world's most common neglected tropical diseases and a leading cause of iron deficiency anemia in low- and middle-income countries. A Human Hookworm Vaccine is currently being developed by the Sabin Vaccine Institute and is in phase 1 clinical testing. The candidate vaccine is comprised of two recombinant antigens known as Na-GST-1 and Na-APR-1, each of which is an important parasite enzyme required for hookworms to successfully utilize host blood as a source of energy. The recombinant proteins are formulated on Alhydrogel(®) and are being tested in combination with a synthetic Toll-like receptor 4 agonist. The aim of the vaccine is to induce anti-enzyme antibodies that will reduce both host blood loss and the number of hookworms attached to the gut. Transfer of the manufacturing technology to the Oswaldo Cruz Foundation (FIOCRUZ)/Bio-Manguinhos (a Brazilian public sector developing country vaccine manufacturer) is planned, with a clinical development plan that could lead to registration of the vaccine in Brazil. The vaccine would also need to be introduced in the poorest regions of Africa and Asia, where hookworm infection is highly endemic. Ultimately, the vaccine could become an essential tool for achieving hookworm control and elimination, a key target in the 2012 London Declaration on Neglected Tropical Diseases.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier Science
dc.rightsopen access
dc.subjectAncilóstomo
dc.subjectheltmintos
dc.subjectNa-GST-1
dc.subjectNa-APR-1
dc.subjectAnemia
dc.subjectHookworm
dc.subjectHelminth
dc.subjectNa-GST-1
dc.subjectNa-APR-1
dc.subjectAnemia
dc.titleThe Human Hookworm Vaccine
dc.typeArticle


Este ítem pertenece a la siguiente institución